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Cytosolic brain-type creatine kinase (BB-CK), which is coexpressed with ubiquitous mitochondrial uMtCK, is signiﬁcantly inacti-
vated by oxidation in Alzheimer’s disease (AD) patients. Since CK has been shown to play a fundamental role in cellular energetics
of the brain, any disturbance of this enzyme may exasperate the AD disease process. Mutations in amyloid precursor protein
(APP) are associated with early onset AD and result in abnormal processing of APP, and accumulation of Aβ peptide, the main
constituent of amyloid plaques in AD brain. Recent data on a direct interaction between APP and the precursor of uMtCK support
an emerging relationship between AD, cellular energy levels, and mitochondrial function. In addition, recently discovered creatine
(Cr) deposits in the brain of transgenic AD mice, as well as in the hippocampus from AD patients, indicate a direct link between
perturbed energy state, Cr metabolism, and AD. Here, we review the roles of Cr and Cr-related enzymes and consider the potential
value of supplementation with Cr, a potent neuroprotective substance. As a hypothesis, we consider whether Cr, if given at an early
time point of the disease, may prevent or delay the course of AD-related neurodegeneration.
Copyright © 2006 Tanja S. B¨ urklen et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
FUNCTION AND SUBCELLULAR LOCALIZATION OF
THE CREATINE KINASE ISOENZYME FAMILY
MEMBERS IN BRAIN
Large amounts of energy are required to maintain the sig-
nalling activities of the cells in the central nervous system
(CNS). The dominant share of energy consumption in the
brain can be assigned to brain function-related processes,
for example, for maintenance of membrane potential by the
Na+/K+-ATPase,Ca2+ homeostasis by theCa2+-ATPase,neu-
rotransmitter processing, intracellular signalling, and axonal
as well as dendritic transport [1]. Mechanisms to facilitate
energy transfer within cells that require ﬂuctuating high en-
ergy levels, such as those in skeletal muscle, heart, and brain,
include the juxtaposition of intracellular sites of ATP gener-
ation with sites of ATP consumption, as well as the transfer
ofhigh-energyphosphatesbetweenthesesitesbythecreatine
kinase (CK)/phosphocreatine (PCr) system [1, 2].
CK is categorized into four isoforms based on its tis-
sueexpression(muscleorbrain)andsubcellulardistribution
(cytosolic or mitochondrial). In sarcomeric muscle, dimeric
cytosolic muscle-type CK (MM-CK) is localized to the M-
band [3], the sarcoplasmic reticulum (SR) [4, 5], and the
plasma membrane. At these sites, MM-CK is functionally
coupled to the myoﬁbrillar acto-myosin ATPase [6–8], the
SR Ca2+-ATPase [4, 5], and the plasma membrane Na+/K+
ATPase [9], respectively, and utilizes PCr for local in situ re-
generation of ATP. In the brain, the dimeric cytosolic form
of CK is called brain-type CK (BB-CK). The octameric mi-
tochondrial CK (MtCK) is classiﬁed into two forms: sar-
comeric muscle form (sMtCK) and brain form called ubiq-
uitous MtCK (uMtCK) [10, 11]. Both MtCKs are located
in the mitochondrial intermembrane space [12], along the
entire inner membrane and also at peripheral contact sites
[13], where inner and outer membranes are in close prox-
imity [14, 15]. There, MtCK can directly transphosphorylate2 Journal of Biomedicine and Biotechnology
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Figure 1: The CK/PCr system.
intramitochondrially produced ATP into PCr [16], which is
then exported into the cytosol.
uMtCK is always coexpressed with dimeric cytosolic BB-
CK[17]atvariouslevelsthroughouttheentirebrain.Incere-
bellum, both of these CK isoforms are found highly concen-
trated in the glomeruli structures of the cerebellar granu-
lar layer. However, the level of BB-CK is much higher than
uMtCK in cerebellar Bergmann glial cells. In addition, both
isoforms are highly expressed in the choroid plexus and in
hippocampal granule and pyramidal cells. The hippocampus
is important for learning and memory and is most severely
aﬀected in AD [18].
Generation of ATP, hence CK activity, is critical for CNS
function. Neurons require a great amount of ATP to main-
tain membrane polarization, Ca2+ inﬂux from organelles,
processing of neurotransmitters, intracellular signalling sys-
tems, and axonal and dendritic transport [1]. Interestingly,
CK is speciﬁcally associated with these important processes.
On a subcellular level, BB-CK has been found in association
with synaptic vesicles [19] and synaptic plasma membranes
[20]. On the other hand, supporting glial cells also require
ATP for neurotransmitter uptake. In the rat hypothalamus,
BB-CK plays an essential role in regenerating ATP for gluta-
mate clearance during excitatory synaptic transmission [21].
Therefore,thenumberofsynapsesandsynapticplasticitycan
be profoundly regulated by ATP levels in neuronal and non-
neuronal cells [22].
During brain development, there is a coincidence in the
timing of maximal expression of BB-CK and myelin basic
protein in the cerebellum which is an indication for a role
of BB-CK in myelination [23]. Both BB-CK and uMtCK lev-
els are increased in a coordinated fashion during postna-
tal brain development [24]. In brain, CK has been shown
to be associated with synaptic membranes [25]a n dt of a -
cilitate glutamate uptake into vesicles [26], thus being di-
rectly involved in the energetics of neurotransmitter uptake.
CK has also been shown to be associated with acetylcholine
receptor-rich membranes [27] and to be involved in quantal
release of acetylcholine in synaptosomes [28]. Further, CK
together with enolase are part of a complex which is involved
in axonal transport [29] and thus support the energetics of
these transport events. CK has also been shown to be func-
tionally coupled to the Na+-K+ ATPase [9, 30], as well as to
the ATP-gated K+-channel [31, 32]. This seems to be impor-
tant due to the fact that about 50% of total brain energy is
used by the Na+ i o np u m p[ 1]. In addition, CK knock-out
mice display a signiﬁcant neurological phenotype [33, 34].
Based on these ﬁndings, a functional CK/PCr energy shuttle
system has been proposed [35], where BB-CK and uMtCK
would constitute an eﬃcient energy buﬀering and shuttle
system in brain [36], similar to that observed in muscle.
THE CREATINE KINASE/PHOSPHOCREATINE
SHUTTLE SYSTEM IN THE BRAIN
As mentioned above, the major energy-consuming process
in neural cells is the transport of ions by the Na+/K+-ATPase
[37]. Even though the cellular pools of ATP are rather small
and the movement of ATP within cells by diﬀusion is slow
[1], no signiﬁcant change in overall ATP levels can be de-
tected during activation of excitable tissues [38]. This is be-
cause ATP is continuously and eﬃciently replenished from
the large pools of PCr through the CK reaction, as has
been shown in detail in muscle cells [39–42]. The CK isoen-
zymes catalyze the reversible transfer of the high-energy N-
phosphoryl group of phosphocreatine (PCr) to ADP to yield
ATP. The concept of the creatine kinase/phosphocreatine
(CK/PCr) shuttle system (Figure 1) describes the functional
association of CK isoenzymes with discrete intracellular
compartments at sites of ATP production and utilization.
Thus, PCr and Cr serve as cytosolic energy transducers to
connect these intracellular sites and together with precisely
localized CK isoenzymes constitute an organizational feature
that increases the eﬃciency of energy metabolism [1, 39, 41].Tanja S. B¨ urklen et al 3
T h eC K / P C rs y s t e mf u n c t i o n sa sat e m p o r a la n ds p a -
tial energy buﬀer, as well as a regulator of cellular energet-
ics [39, 42, 43]. It maintains high global ATP/ADP ratios by
preventing a rise in intracellular free ADP and thus preserves
the thermodynamic eﬃciency of ATPases even at high cel-
lular ATP turnover [36]. By this mechanism, an inactivation
of cellular ATPases by rising [ADP] is avoided and a net loss
of adenine nucleotides is prevented [39, 44, 45]. Thus, the
CK/PCr system is a rapidly available source for ATP trans-
port and resynthesis not only in muscle but also in the brain.
The high activity of CK in the brain, together with high con-
centrations of its substrates, PCr and Cr, as well as the phe-
notype of mice deﬁcient in brain-type CK isoforms [34, 35]
and the eﬀects of Cr supplementation on brain function (see
below) strongly indicate that CK is a key enzyme in brain en-
ergy metabolism [46] and that PCr is an important energy
reservoir and energy transport molecule [47]. A schematic
drawing of the subcellular micro-compartmentation of CK
enzymes and their colocalization with ATP-producing and -
consuming sites within the cell is depicted in Figure 1 (from
Schlattner U and Wallimann T. Metabolite channeling: crea-
tine kinase micro compartments, to (Lennarz WJ, and Lane
MD, eds.) Encyclopedia of Biological Chemistry. Vol 2. New
York, USA: Academic Press; (2004):646–651; with permis-
sion by ELSEVIER Publishing Company).
Isoenzymes of CK are found in diﬀerent compartments
such as mitochondria (a) and the cytosol (b)–(d) in a soluble
form (c) or associated to a diﬀerent degree to ATP-delivering
processes, for example, mitochondrial oxidative phosphory-
lation (a) or glycolysis (b) or to ATP-consuming processes,
like ATPases or other ATP-requiring or ATP-regulated pro-
cesses (d). A large cytosolic PCr pool up to 30mM is built
up by CK using ATP generated by oxidative phosphoryla-
tion (a) or glycolysis (b). PCr is then used to buﬀer global
(c) and local (d) ATP/ADP ratios. In cells that are polar-
ized and/or have a very high or localized ATP consump-
tion, these CK isoenzymes, together with easily diﬀusible
PCr, also maintain an energy shuttle between ATP-providing
and ATP-consuming processes (a), (d). Metabolite channel-
ing occurs where CK is associated with ATP-providing or
ATP-consuming transporters, ion pumps, or enzymes that
are operating also in brain (a), (d). Cr is synthesized mostly
in kidney and liver. Cells can take up Cr from the blood
stream by a speciﬁc creatine transporter CRT. In brain, CRT
isprominentlylocalizedattheblood-brainbarrier,butisalso
seen on the plasma membrane of neurons [48–51].
Details on the importance of CK and its substrates for
brain function are revealed by recent studies on the neu-
rological and behavior phenotype of CK knockout mice
[33, 34]. Mice lacking the expression of one CK isoform,
cytosolic BB-CK or uMtCK, display abnormalities in for-
mation and maintenance of hippocampal mossy ﬁbre con-
nections and in behaviors such as habituation, spatial learn-
ing, and seizure susceptibility [34]. On the other hand, adult
micelackingbothBB-CKanduMtCK,theso-calledCKdou-
ble knockout mice, display reduced body weight and are
severely impaired in spatial learning in both dry and wet
maze, and display lower nest building activity and acoustic
startle reﬂex responses [34]. Morphological analysis of CK
double knockout brains revealed a reduction of brain weight
and hippocampal size, a smaller regio-inferior area, and
relatively larger supra-pyramidal and intra-infra-pyramidal
mossy ﬁber area [34]. These results suggest that the lack of
both brain-speciﬁc CK isoforms renders the synaptic cir-
cuitry less eﬃcient in coping with sensory or cognitive activ-
ity related challenges in the adult brain and fully support the
physiological importance of CK for normal brain function.
CREATINE SYNTHESIS AND UPTAKE IN BRAIN
In vertebrates, Cr is synthesized mostly in the liver and kid-
ney and is then transported through the blood and taken up
by target tissues with high energy demands. Cr biosynthesis
involves two sequential steps catalyzed by L-arginine: glycine
amidinotransferase (AGAT) and S-adenosylmethionine:gu-
anidinoacetate N-methyltransferase (GAMT) [51]. It has
been shown that a certain amount of Cr is synthesized en-
dogenously in the developing brain [51–53], and recently
bothAGATandGAMT,aswellascreatine transporter(CRT)
have been identiﬁed and localized in distinct cellpopulations
of the developing brain [51, 52]. GAMT immunoreactivity
is very strong in oligodendrocytes, moderate in astrocytes,
and not detected in embryonic neurons. These observations
led to the conclusion that Cr in neurons is derived in part
from local glial populations surrounding the neurons, indi-
catinganovelneuron-glialrelationshipinvolvingCrtraﬃck-
ing [49]. However, the majority of Cr seems to get taken up
continuously through the blood-brain barrier by CRT [48],
which works against a huge Cr gradient [54]. Nevertheless,
certain brain cells seem to have the capacity for endogenous
Cr biosynthesis, especially in the developing brain [51]. Pa-
tients with genetic CRT-deﬁciency lack any detectable Cr in
the brain [55] and have severe neurological phenotypes in-
cluding hypotonia, developmental speech delay, autism, and
brain atrophy [55, 56]. These cases emphasize the impor-
tance of the substrates of CK, Cr, and PCr, for normal brain
function in man.
DISTURBED ENERGY METABOLISM IN
NEURODEGENERATIVE DISEASES
A common feature of severe neurodegenerative disorders,
suchasHuntington’sdisease(HD),Amyotrophiclateralscle-
rosis (ALS), Parkinson’s disease (PD), and AD are mutations
in nuclear or mitochondrial DNA. This leads to secondary
mitochondrial dysfunction accompanied by a more or less
severely disturbed energy metabolism as well as a disturbed
energetic status of the brain [57]. Cellular energy reserves
are important for normal brain function, however, the cel-
lular energy state also appears to play a key role in regulat-
ing and initiating apoptosis or necrosis of brain cells, since
mitochondria are known to be essential in controlling spe-
ciﬁc apoptotic pathways [58]. For example, in patients with
ALS, a chronically deﬁcient intake of energy [59], increased
mitochondrial volume (swelling), oxidative damage, and de-
creased complex I activity have been observed [60]. Further,4 Journal of Biomedicine and Biotechnology
a loss of mitochondrial membrane potential and chronically
elevated cytosolic Ca2+-levels accompany these observations
[61].
One of the most important hallmarks in the pathogen-
esis of senile dementia of the Alzheimer type (AD) is the
marked decrease of cerebral glucose metabolism [62] caused
by disturbed acetyl-CoA synthesis and critically lowered ox-
idative phosphorylation [63]. Measurement of local cerebral
glucosemetabolismbypositronemissiontomography(PET)
has become a standard technique to study dementia [64].
By this method, a regional impairment of cerebral glucose
metabolism in neocortical association areas in the brains of
ADpatientscouldbeshown[64].Inaddition,corticalacetyl-
choline esterase activity is signiﬁcantly lower in patients with
AD compared to age-matched normal controls [64]. A de-
crease of the oxidative energy metabolism in senile dementia
and the resulting ATP deﬁcit may thus change protein degra-
dation,synaptic transmissionandionhomeostasis[63].Fur-
thermore, disturbed function and abnormal morphology of
mitochondria are also associated with AD and PD [65].
Aglobaldecreaseincerebralmetabolicratealsooccursin
AD and in other dementias, and the AD brain is character-
ized by a variable, but often marked, loss of neurons, a depo-
sition of extracellular plaques, and intracellular neuroﬁbril-
lary tangles [66–68]. Impaired energy metabolism [68]a n d
altered cytochrome c oxidase activity are among the earli-
est detectable defects in AD [69–72]. Most recently, focal
deposits of Cr have been discovered in AD [73], suggestive
of a perturbed energetic status and deregulated Cr synthesis
and/or uptake (see further below).
MITOCHONDRIAL ASPECTS OF NEURODEGENERATION
The involvement of mitochondria in neurological disorders
is frequently discussed. It is known that pathological states
and mitochondrial dysfunction often lead to the excessive
generation of free radicals and subsequent oxidative damage
[74]. Studies of AD patients have identiﬁed decreased com-
plex IV activity and mitochondrial DNA mutations [75, 76].
Recently, a role for mitochondria has been indicated in Aβ-
induced apoptosis. The Aβ-binding alcohol dehydrogenase
(ABAD) has been reported to interact with Aβ in the mi-
tochondria of AD patients and transgenic mice [77]a n d
to potentiate Aβ-induced apoptosis and free-radical gener-
ation in neurons. Furthermore, in brains from patients with
autopsy-conﬁrmed AD and clinical dementia ratings before
death, the activity of tricarboxylic acid cycle (TCA) enzymes
(pyruvate dehydrogenase complex, isocitrate dehydrogenase,
andthealpha-ketoglutaratedehydrogenase)ofmitochondria
were signiﬁcantly decreased. Changes in TCA cycle activities
correlated with the clinical state of the disease, suggesting a
coordinated mitochondrial alteration [77]. Recently, a struc-
tural and functional interplay between dendritic mitochon-
dria and spines/synapses was discovered in in vitro cultured
neurons [78]. A small fraction of mitochondria is present
within dendritic protrusions of cultured neurons [78]. In-
terestingly, in these cultured neurons, Cr supplementation
enhances mitochondrial activity and causes a higher density
of spines and synapses. Remarkably, the ability of neurons
to form new excitatory synapses in response to stimulation
is also correlated with increased activity of dendritic mito-
chondria [78]. Neuronal activity itself aﬀects the motility,
fusion/ﬁssion balance, and subcellular distribution of mito-
chondria in dendrites, depending on calcium inﬂux. This
seems to be physiologically relevant, because repetitive de-
polarization that stimulates synapse formation causes the re-
distributionofmitochondriaintodendriticprotrusions[78].
These results suggest a local involvement of mitochondria in
synapse formation and development. Taken together, these
ﬁndings are in agreement with the concept that the charac-
teristic loss of synapses in disorders like AD arises in part
from mitochondrial dysfunction [79].
PERTURBED CK FUNCTIONS AND LOWER PCR/CR
RATIOS ARE LINKED TO NEURODEGENERATIVE
DISEASES INCLUDING AD
Oxidative alterations of proteins and lipids have been im-
plicated in the progression of neurodegenerative disorders
[80, 81]. Protein carbonyls, considered a marker of pro-
tein oxidation, are increased in AD [82]. Using a proteomic
approach, BB-CK, glutamine synthase (GS), and ubiquitin
carboxy-terminal hydrolase l-1 (UCH L-1) were identiﬁed as
the three major speciﬁcally oxidized proteins in AD brains
[83]. Oxidative modiﬁcation of CK rapidly inactivates the
enzyme and results in abnormal partitioning of CK between
the soluble and pellet fractions [84]. As a consequence, CK
activity in AD brain homogenates is decreased by 86%, as
shown by [alpha 32P]8N3ATP incorporation into the en-
zyme, but the expression level of CK is decreased by less
than 14% [84]. These ﬁndings can be explained by the fact
that all CK isoforms possess a highly reactive cysteine residue
that is speciﬁcally modiﬁed by sulfhydryl reagents or oxy-
gen or peroxynitrite radicals [85]. Loss of BB-CK activity
[82, 84, 86, 87], resulting from its oxidation [87], implies
that the maintenance of a healthy cellular energy state is per-
turbed in the AD brain and that energy supply in glia cells,
neurons, and synaptic elements is altered. This is corrobo-
rated by one study, where Alzheimer’s patients were found to
have reduced levels of brain PCr in early stages of the disease
and decreased oxidative metabolism in later stages compared
to healthy persons, indicating that the AD brain is under en-
ergetic stress [88].
FORMATION AND PRESENCE OF FOCAL CREATINE
DEPOSITS IN AD BRAIN
The recent discovery of Cr deposits in the brains of trans-
genic APP mice by Fourier transform infrared microspec-
troscopy (FTIR) in frozen and desiccated brain slices [73]
raises many questions concerning its role in AD. At present,
itisnotknownwhetherthecreatineexistsasprecipitatedmi-
crocrystals or as localized, sequestered pools in vivo. In this
section, we speculate on some possible origins for these de-
posits.Tanja S. B¨ urklen et al 5
Cr is a very prominent compound in both muscle and
brain, where total Cr (PCr plus Cr) may reach 50mM or
20mM, respectively, the latter being strongly dependent on
the region of the brain [36]. Intracellularly, under normal
energetic conditions, 2/3 of total Cr is in the form of energy-
rich PCr and 1/3 in the form of Cr. During cellular energy
stress, the PCr/Cr ratio decreases. Cr is less insoluble than
PCr, having a solubility limit of roughly 100mM in aqueous
solution, depending on temperature and pH. Thus, in gly-
colytic skeletal muscle that is highest in total Cr, this solubil-
ity limit is nearly reached if all PCr was converted to Cr. In
brainthisislesslikely,giventhelowertotalCrconcentration.
However, it is conceivable that upon massive destruction of
neurons in AD accompanied by lysis and cell death, signif-
icant amounts of Cr are set free within the region of brain
cell destruction. Thus, if concentrated, Cr might precipitate
in the extracellular space of the brain, giving rise to focal de-
posits in vivo. However, no such neuronal loss is observed
in the transgenic APP mice, nor are there obvious changes
in cell morphology that would support such a hypothesis. In
fact, the focal Cr deposits are seen in frozen brain sections
that have to be desiccated before FTIR microspectroscopy
measurements [73]. It is therefore not unreasonable to sup-
pose that under in vivo (hydrated) conditions, the elevated
Cr exists in solution, for example, inside intact cells or in
vacuoles or other subcellular compartments, and that this
Cr only solidiﬁes into focal microcrystals when the tissue is
dried.
Another explanation is based on a breakdown in the syn-
thesisand/orneuronaluptakepathwayofCr.Someglialcells,
especially oligodendrocytes, synthesize Cr, which is then re-
leasedtobetakenupbyneurons[49,51].ADisaccompanied
by inﬂammation and an increase in the number of glial cells,
providing an additional source of Cr. Neurons normally take
up Cr from the extracellular space by CRT. If, however, neu-
rons were energetically stressed, Cr uptake could be limited,
because the uptake of Cr via CRT is accompanied by con-
comitant Na+ and Cl− cotransport into the cell [54]. This
Na+ has to eventually be pumped out of the cell by the ATP-
driven Na+/K+-ATPase that also uses a major part of cellular
energy [30]. Thus, if Cr uptake into neurons was hampered,
the net result would be a slow accumulation of Cr in the ex-
tracellular space.
A third possibility is that the oxidation of BB-CK and
uMtCK [85] limits the formation of PCr, which is in turn
depleted to support ADP to ATP conversion, thus favoring
the generation of excess Cr.
Our recent data (see below) raise yet another possibility
that uMtCK targeting to the mitochondria may be disrupted
byalossofAPPfunction[89],whichinturnwouldresultina
decreaseinsynthesisofPCrandaconcomitantaccumulation
of Cr within cells.
Since the microdeposits of Cr detected by FTIR mi-
crospectroscopy are found distributed focally across large re-
gions of the hippocampus in the transgenic AD model mice
[73], occasionally colocalized on the edges of AD plaques,
it is likely that at least some of the Cr deposits are not in-
tracellular, but rather in the extracellular space. They could
be generated either by Cr leakage from dying cells or by im-
paired Cr traﬃcking between glia and neurons, as outlined
above. However, irrespective of primary course, the factor
triggering Cr deposits would be a disturbed energy charge
of neurons under stress.
INTERACTION AND COMPLEX FORMATION
OF APP WITH MITOCHONDRIAL
CREATINE KINASE
Recent biochemical data from our laboratories provide a di-
rect link between APP and uMtCK and shed new light on
putative molecular mechanisms that lead to energetic abnor-
malities in AD brain (discussed above) [89]. Using a func-
tional proteomic screen, in which APP interacting proteins
were isolated based on their biochemical aﬃnity and identi-
ﬁed by peptide mass ﬁngerprinting, we found that the short
cytoplasmic tail of APP family proteins interacts with sev-
eral diﬀerent mitochondrial targeted proteins (see [89]a n d
Li and Homayouni, unpublished observations). This inter-
action was of high aﬃnity toward the preprotein forms, con-
taining the N-terminal signal sequence, of the mitochondrial
proteins. Importantly, coexpression of APP C-terminal re-
gions dramatically stabilized uMtCK in cultured cells. APP
family proteins are type-I transmembrane glycoproteins that
undergo sequential N- and O-linked glycosylation in the
ER/Golgipathway.Usingco-immunoprecipitationassays,we
found that uMtCK associated with the full-length but lower
molecular weight APP proteins, suggesting that the interac-
tion occurs prior to maturation of APP proteins. Immuno-
histochemical analysis indicated that APP and uMtCK colo-
calize in ER/Golgi and not in mitochondria of cultured pri-
mary neurons as well as in transiently transfected nonneu-
ronal cells. These results raise the possibility that APP fam-
ily proteins may function as cytoplasmic chaperone-like pro-
teins to stabilize mitochondrial proteins such as uMtCK. In-
deed,APPisinducedandaccumulatesintheER/Golgiofcul-
tured cells after treatments that induce oxidative metabolic
stress or ER stress via disruption of the ER folding machin-
ery, thus aﬀecting protein maturation and causing accumu-
lation of unfolded proteins within the ER lumen [90, 91]. In
turn, some evidence indicates that APP induction can play a
protective role against cell stress and axonal injury [91, 92].
Why then only mutations in APP, and not its other fam-
ily members, have been linked to AD? We propose that mu-
tations in APP result in a dual attack on the mitochondria.
First, these mutations enhance the generation of Aβ pep-
tide [93], which were shown to be directly toxic to mito-
chondria through an interaction with ABAD [77]. Second,
based on our recent data, we speculate that the loss of the
normal function of APP in targeting of uMtCK, and perhaps
other mitochondrial proteins to the mitochondria, would re-
sult in a further compromise of mitochondrial function in
the aﬀected neurons. This hypothesis is consistent with a
stochastic model proposed by Clarke and colleagues [94], in
which the mutated cell exists in an altered steady state and
upon a random insult initiates a cascade of events result-
ing in cell death. It has been shown that mutations in APP6 Journal of Biomedicine and Biotechnology
increase the vulnerability of cells to oxidative stress [91, 95].
Although, these ﬁndings pertain to APP mutations, which
are linked only to early-onset AD, they suggest a more gen-
eral mechanism for the pathogenesis of AD involving dysreg-
ulation of mitochondrial function [65, 96, 97].
NEUROPROTECTIVE EFFECTS OF
CR SUPPLEMENTATION FOR
NEURODEGENERATIVE DISEASES
Over the past decade, the ergogenic beneﬁts of synthetic Cr
monohydrate have made it a popular dietary supplement,
particularly among athletes [98]. The anabolic properties of
Cr also oﬀer hope for the treatment of diseases characterized
by muscle weakness and atrophy, as well as for rehabilitation
[99]. In serum-free cultured cells, Cr supplementation has
been shown to protect rat hippocampal neurons against glu-
tamate and Aβ toxicity [100]. In an animal model of trau-
matic brain injury (TBI), it has been shown that Cr supple-
mentation protects against neuropathology of TBI through
mechanisms involving maintenance of mitochondrial bioen-
ergetics and preservation of ATP levels [101]. This is due
to the fact that newly entered Cr is phosphorylated inside
the cell by the catalytic activity of CK, leading to an in-
creased PCr/ATP ratio and, thus, a higher energy charge in
the cell. Brustovetsky et al demonstrated neuroprotective ef-
fects of PCr and Cr pretreatments against energetic depri-
vation caused by 3NP and glutamate excitotoxicity in cul-
tured neurons [102]. There, surprisingly, extracellular PCr
was more eﬃcacious than Cr. This could be explained by the
fact that PCr is able to bind to and stabilize cell membranes
[103].
Recentdatausinghumanfetalstriatalandmesencephalic
tissue identiﬁed Cr as a potent natural survival and neuro-
protective factor for GABA-ergic neurons in a model for HD
[104] and of dopaminergic neurons in a model for PD [105–
107]. Cr is also beneﬁcial in animal models of cerebral is-
chemia [108–110] and spinal cord injury [111, 112]. In the
G93A transgenic mouse model for ALS, long-term Cr sup-
plementation extends life span, signiﬁcantly improves mo-
tor coordination [113], and reverts the cholinergic deﬁcit in
some forebrain areas at an intermediate stage of ALS [114].
In rat and mouse models of cerebral ischemia, oral Cr ad-
ministration resulted in neuroprotection and remarkable re-
ductioninischemicbraininfarction[109,115].Postischemic
caspase-3 activation and cytochrome c release were signiﬁ-
cantly reduced in creatine-treated mice. Cr administration
buﬀered ischemia-mediated cerebral ATP depletion [115].
These authors suggest that a prophylactic Cr supplementa-
tion, similar to what is recommended for an agent such as
aspirin, may be considered for patients in high stroke-risk
categories.
Supplementation with Cr has been used as an adjuvant
to a therapeutic scheme in numerous diseases associated
with muscle and neuromuscular degeneration. To date, two
clinical pilot trials to test the eﬃcacy of Cr monohydrate
in ALS have been completed without any measurable im-
provements in overall survival or in a composite measure of
muscle strength [116, 117]. However, these pilot studies were
powered only to detect a 30–50% or greater change in rate of
decline of muscle strength. These trials raised new questions
about the optimal dosage of Cr and its beneﬁcial eﬀects on
muscle fatigue, a measure distinct from muscle strength. A
large multicenter clinical trial is currently underway to fur-
ther investigate the eﬃcacy of Cr monohydrate in ALS and
to address these unresolved issues. To date, evidence shows
that Cr supplementation at 5–10 grams over a time period of
12 months has a good safety proﬁle and is well tolerated by
patients with ALS.
In a trial with HD patients, Cr supplementation low-
ered brain glutamate levels [118]. Very recent data from a
randomized, double-blind, placebo-controlled study with 64
subjects with Huntington’s disease (HD), 8g/day of Cr ad-
ministered for 16 weeks, show that Cr was well tolerated and
safe. Serum and brain Cr concentrations increased in the
Cr-treated group and returned to baseline after washout. In-
triguingly, serum 8-hydroxy-2’-deoxyguanosine (8OH2’dG)
levels, an indicator of oxidative injury to DNA, were mar-
kedly elevated in HD, but were reduced signiﬁcantly by
Cr treatment [119]. In patients with a novel cytochrome
b mutation, Cr supplementation attenuated the production
of free radicals and the paracrystalline intramitochondrial
inclusions [120] brought about by crystallization of over-
expressed MtCK inside mitochondria [121]. The rationale
for the use of Cr along with available evidence from animal
modelsandclinicaltrialsforALSandrelatedneurodegenera-
tive or neuromuscular diseases have been described in [122].
Thus,itisobviousthatCrasasimplenutritionalsupplement
shows a great potential for neuroprotective eﬀects in various
neuromuscular and neurodegenerative diseases.
RATIONALE FOR CREATINE SUPPLEMENTATION IN
ALZHEIMER’S DISEASE
Very recent data by Snyder et al show that Aβ addition to
cortical neurons in cell cultures leads to internalization of
NMDA-receptors with concomitant dephosphorylation of
theNMDAreceptorsubunitNR2BatTyr1472[123].Sinceit
has been shown earlier that Cr supplementation signiﬁcantly
protectsneurons againstAβ neurotoxicity [100],itcanbein-
ferred that Cr may indirectly beneﬁt AD patients by reducing
the eﬀects of Aβ toxicity and NMDA-receptor internaliza-
tion. It may also alleviate the deterioration of glutamatergic
neurotransmission and synaptic plasticity that are vital for
learning and memory. For example, treatment of hippocam-
palneuronswith20mMCrsigniﬁcantlyincreasedbothbasal
and activity dependent synaptogenesis [78]. In two studies,
Cr supplementation has been shown to improve mental con-
centration [124], as well as memory and learning [125]i n
healthy human subjects. It is possible that this will also be
true for early stage AD patients.
Given the evidence for metabolic dysfunction in AD, we
hypothesize that Cr supplementation at an early time point
of the disease might be useful in compensating for the dis-
turbed energy metabolism in subjects with AD by replen-
ishing the energy pools, activating mitochondrial respirationTanja S. B¨ urklen et al 7
[126,127]andprotectingcellsfromapoptosis[127,128].Al-
though Cr cannot increase energy charge if CK is damaged,
for example, by oxidative damage (see below), very early in
the course of AD, CK is still functioning to some extent,
so it is reasonable to assume that Cr may be of beneﬁt in
those early phases. Further, CK isoenzymes are known to be
prime targets of oxidative damage by free radicals [85–87]
that are a hallmark of many neuromuscular and neurode-
generative diseases. The substrate Cr, together with MgADP
or MgATP, upon forming a transition state complex in the
active site of CK, has a protective eﬀect against inactivation
of CK isoenzymes by free radicals, such as oxygen radicals
and peroxynitrite. In the case of MtCK, Cr in the presence
of nucleotide, additionally prevents the dissociation of na-
tive octameric MtCK into dimers [85]. Thus, an elevation of
the intracellular concentration of Cr by Cr supplementation
may confer additional protection to CK and concomitantly
delay the free-radical induced inactivation of the CK system
i nb r a i nt h a ti ss e e ni nA D[ 87].
Cr might be expected to improve energetic conditions
for all cells, as well as for “at risk neurons,” in animal mod-
els of neurodegenerative diseases, providing temporary pro-
tection. Such protection would occur in a vital time period
when cell fate is still in balance, or perhaps precritical, before
secondary excitotoxicity might threaten weakened neurons.
Such protection by Cr, however, could only be expected if
the CK system were not compromised in a signiﬁcant way
such that PCr would still be synthesized by CK. An addi-
tional mechanism by which Cr may exert neuroprotection,
could be through activation of AMPK in the brain, in a man-
nersimilartothatrecentlyshowninmusclecells[129].Since
AMPK is a cellular energy sensor and fuel gauge, this would
lead to short-term and long-term compensatory reactions to
help the cells recruit more energy sources, for example, by
up-regulation of glucose transport and elevation of fatty acid
oxidation [130].
Lastly, Cr may exert neuroprotection by reducing pro-
tein aggregation. For example, Cr was found to reduce
transglutaminase-catalyzed protein aggregation, in vitro,
[131] a process thought to be relevant for the formation
of protein aggregate formation in several neurodegenerative
diseases, including Alzheimer’s, Parkinson’s, and Hunting-
ton’s disease.
Thus, one may postulate that Cr supplementation, in
combination with other established clinical interventions,
maybeaveryvaluableadjuncttherapyforpatientsatanearly
stage of the disease progression. However, additional studies
are needed ﬁrst to address the questions of where exactly the
microcrystalline Cr deposits are located, for example, intra-
or extracellularly, and whether they are associated with spe-
ciﬁc structures of the brain. In addition, it would be impor-
tant to be able to quantify Cr in these deposits. Since these
focal Cr microdeposits are observed in the brain of trans-
genic APP mice, as well as AD patients [73], there is a valid
concern that supplementation with extra Cr might exacer-
bate rather than ameliorate this situation. However, as rea-
soned above, Cr, if given at an early time point of disease,
may prevent or delay the formation of Cr deposits that are
a consequence of cellular pathology. In any case, Cr supple-
mentation should be tested ﬁrst on the transgenic APP mice
in which the Cr deposits have been found. In the long term,
if warranted by the outcome of such tests, further trials with
ADpatientscouldbeperformed.Ifsuccessful,thischeapand
safe intervention, involving as a nutritional supplement, may
extend a huge socioeconomic beneﬁt by improving the qual-
ity of life of AD patients and lowering exploding health care
costs.
ABBREVIATIONS
3NP 3-nitropropionic acid
8OH2’dG 8-hydroxy-2’-deoxyguanosine
Aβ amyloid beta peptide
ABAD Aβ-binding alcoholdehydrogenase
AD Alzheimer’s disease
AGAT L-arginine:glycine amidinotransferase
ALS amyotrophic lateral sclerosis
AMPK AMP-stimulated protein kinase
APP amyloid precursor protein
BB-CK cytosolic brain-type creatine kinase
CK creatine kinase
CNS central nervous system
Cr creatine
CRT Na+ and Cl− dependent creatine transporter
FTIR Fourier transform infrared
GAMT S-adenosylmethionine:guanidinoacetate
N-methyltransferase
HD Huntington’s disease
MM-CK cytosolic muscle-type creatinekinase
PCr phosphocreatine
PD Parkinson’s disease
PET positron emission tomography
sMtCK sarcomeric mitochondrial creatine kinase
SR sarcoplasmic reticulum
TBI traumatic brain injury
TCA tricarboxylic acid
UCH L-1 ubiquitin carboxy-terminal hydrolase l-1
uMtCK ubiquitous mitochondrial creatine kinase
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